Who are Gardasil9's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gardasil 9 Suspension for Injection, Gardasil 9 rescue dose, Active Comparator: GARDASIL ®9, GSK580299, GSK Biological's HPV vaccine, GSK580299 (CervarixTM).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gardasil9.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Gardasil9 — Competitive Intelligence Brief

Gardasil9 (Gardasil9) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant HPV vaccine. Area: Oncology / Immunology.

marketed Recombinant HPV vaccine HPV L1 capsid protein (types 6, 11, 16, 18, 31, 33, 45, 52, 58) Oncology / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Gardasil9 (Gardasil9) — Boston Medical Center. Gardasil9 is a recombinant vaccine that stimulates the immune system to produce antibodies against nine types of human papillomavirus (HPV) to prevent infection and associated cancers.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Gardasil9 TARGET	Gardasil9	Boston Medical Center	marketed	Recombinant HPV vaccine	HPV L1 capsid protein (types 6, 11, 16, 18, 31, 33, 45, 52, 58)
Gardasil 9 Suspension for Injection	Gardasil 9 Suspension for Injection	Erasmus Medical Center	marketed	Recombinant HPV vaccine	Human papillomavirus L1 capsid protein (types 6, 11, 16, 18, 31, 33, 45, 52, 58)
Gardasil 9 rescue dose	Gardasil 9 rescue dose	Boston Medical Center	marketed	Recombinant HPV vaccine	Human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, 58
Active Comparator: GARDASIL ®9	Active Comparator: GARDASIL ®9	Shanghai Bovax Biotechnology Co., Ltd.	phase 3	Recombinant HPV vaccine	Human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, 58
GSK580299, GSK Biological's HPV vaccine	GSK580299, GSK Biological's HPV vaccine	GlaxoSmithKline	phase 3	Recombinant HPV vaccine	Human papillomavirus (HPV) virus-like particles
GSK580299 (CervarixTM)	GSK580299 (CervarixTM)	GlaxoSmithKline	phase 3	Recombinant HPV vaccine	Human papillomavirus types 16 and 18 (L1 capsid protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant HPV vaccine class)

Boston Medical Center · 2 drugs in this class
GlaxoSmithKline · 2 drugs in this class
Erasmus Medical Center · 1 drug in this class
Shanghai Bovax Biotechnology Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gardasil9 — Competitive Intelligence Brief. https://druglandscape.com/ci/gardasil9. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab